Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.40 – $11.00
100% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.24B | $12.47B | $14.29B | $14.04B | $13.36B | $16.50B | $17.96B | $20.70B |
| Cost of revenue | $0 | $0 | −$1.0M | −$1.0M | −$1.0M | $0 | $0 | $333.1M |
| Gross profit | $11.24B | $12.47B | $14.29B | $14.04B | $13.36B | $16.50B | $17.96B | $20.36B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.4% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $3.90B | $4.48B | $6.35B | $6.46B | $5.70B | $7.48B | $7.72B | $9.80B |
| EBITDA | $4.37B | $4.29B | $6.63B | $6.66B | $6.88B | $9.62B | $8.27B | $10.13B |
| Net income | $3.25B | $2.30B | $3.47B | $4.07B | $4.52B | $6.52B | $5.25B | $6.42B |
| Net margin | 28.9% | 18.4% | 24.3% | 29.0% | 33.8% | 39.5% | 29.2% | 31.0% |
| EPS (diluted) | 80.61 | 57.40 | 86.77 | 101.87 | 113.37 | 163.77 | 132.16 | 162.98 |
Annual figures · source: Financial Modeling Prep
SPARX ASSET MGMT CO
No one on the platform currently holds SRXXF.
No tracked institution reports a position in SRXXF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $47.0000 | |
| 2026-09-30 | $47.0000 | |
| 2026-03-31 | $90.0000 | 2026-06-08 |
| 2025-03-31 | $68.0000 | 2025-06-09 |
| 2024-03-28 | $66.0000 | 2024-06-10 |
| Execution date | Ratio |
|---|---|
| 2022-09-29 | 1-for-5reverse |
No one on the platform has traded SRXXF yet.
| $302M |
| — |
| IMMFFOmni Bridgeway Limited | $1.18 | +1.29% | $342M | — |
| IPXAFImpax Asset Management Group plc | $1.87 | +35.51% | $227M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× earnings vs its 0.1× historical median P/E.
Fair value ≈ $9.65 · price $11.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals $SRXXF $ONC $WXXWY $ASPHF $NVO $LBTSF $TAK https://talkmarkets.com/content/global-markets/week-in-review-chinas-biopharmas-announce-25-billion-in-deals?post=416219&userid=123969
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.